Compare Rockwell Automation (ROK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs TransMedics Group Inc — how do they compare? Rockwell Automation trades at $432.59 (market cap $48.21B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Rockwell Automation is far larger — about 17.6× TransMedics Group Inc's market cap, and Rockwell Automation pays a 1.27% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and TransMedics Group Inc for 24 Days on average.
| ROK | TMDX | |
|---|---|---|
Market Cap | $48.21B | $2.74B |
Volume | 953,342 | 949,331 |
Sector | Industrials | Health |
52-Week High | $495.08 | $150.42 |
52-Week Low | $333.75 | $61.99 |
Typical Hold Time | 74 Days | 24 Days |
Enterprise Value | $51.34B | $3.13B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $434.14, down 1.76% on the day, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Key financials show strong profitability with a 49.09% gross margin and 34.47% ROE, though the P/E ratio of 40.65 suggests a premium valuation. Recent news highlights the company's focus on industrial automation growth, cybersecurity, and AI integration.
The outlook is mixed: analyst consensus is a Buy with a $489.89 price target, but technicals indicate near-term pressure. Investment opportunities lie in continued earnings beats and automation demand, while risks include high valuation sensitivity and macroeconomic headwinds affecting industrial spending.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
